Takeda to discontinue cell therapy efforts

Takeda (TAK) announced that as part of a strategic portfolio prioritization process, the company has made the decision to discontinue its cell therapy efforts. “Takeda will seek an external partner to leverage its cell therapy platform technologies and to further advance the company’s research and clinic-ready programs in this field. The company has no current active clinical trials utilizing cell therapy technology. Takeda will refocus near-term investments into programs that it believes can deliver transformative therapies to patients at increased speed and scale. The company’s preclinical programs utilizing its in-focus modalities, including small molecules, biologics, and antibody-drug conjugates, are advancing novel and highly innovative therapeutic candidates. Takeda’s preclinical research programs will continue to benefit from the novel insights gained from its cell therapy research. In the second quarter of the fiscal year ending March 31, 2026 (FY2025), Takeda expects to recognize an impairment loss of approximately JPY 58.0 billion, primarily related to intangible assets associated with the gamma delta T-cell therapy platform. The majority of this impact is expected to be absorbed by the JPY 50.0 billion of impairment losses on intangible assets associated with products, including in-process R&D, included in Takeda’s full-year consolidated forecast for FY2025 announced on May 8, 2025. Takeda will continue to assess any other related impacts and, to the extent necessary, reflect them in the second quarter financial results and full-year consolidated forecast, which is scheduled to be announced on October 30, 2025,” the company stated.